The Effect and Safety of 5-HT_1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis

Table 3

RRs and 95% CI for secondary outcomes of lasmiditan at 2 h after the first dose.

Comparisons	Headache relief at 2 h			Use of rescue medication (2–24 h)			No/mild disability at 2 h			Global impression of change (very much/much better) at 2 h
		RR (95% CI)			RR (95% CI)			RR (95% CI)			RR (95% CI)
Placebo comparisons
Lasmiditan 50 mg vs. placebo	3	1.27 (1.15, 1.41)	0%	3	0.88 (0.72, 1.07)	0%	3	1.13 (1.03, 1.25)	0%	3	1.33 (1.13, 1.55)	0%
Lasmiditan 100 mg vs. placebo	3	1.51 (1.25, 1.82)	75%	3	0.75 (0.61, 0.92)	0%	3	1.23 (1.08, 1.40)	58%	3	1.60 (1.42, 1.81)	25%
Lasmiditan 200 mg vs. placebo	3	1.41 (1.28, 1.54)	20%	3	0.81 (0.66, 0.99)	0%	3	1.16 (1.03, 1.30)	46%	3	1.62 (1.43, 1.82)	0%
Dosage comparisons
Lasmiditan 50 mg vs. 100 mg	2	0.81 (0.60, 1.09)	73%	2	1.20 (0.94, 1.55)	41%	2	0.90 (0.82, 0.98)	0%	2	0.86 (0.75, 0.99)	38%
Lasmiditan 100 mg vs. 200 mg	3	1.01 (0.95, 1.08)	22%	3	0.95 (0.77, 1.18)	0%	3	1.05 (0.99, 1.13)	0%	3	0.99 (0.90, 1.09)	0%
Lasmiditan 200 mg vs. 50 mg	2	0.98 (0.72, 1.34)	67%	2	1.04 (0.82, 1.33)	36%	2	0.94 (0.86, 1.03)	0%	2	1.16 (1.01, 1.34)	0%

(significant difference). : number of trials; RR: risk ratio; 95% CI: 95% confidence intervals.